Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

and ribavirin
  • 24 weeks of total treatment, with R7128 1000mg bid in combination with pegylated interferon and ribavirin for 8 weeks, followed by a further 16 weeks of pegylated interferon and ribavirin
  • 48 weeks of total treatment, with R7128 1000mg bid in combination with pegylated interferon and ribavirin for 12 weeks, followed by a further 36 weeks of pegylated interferon and ribavirin.
  • A control arm with pegylated interferon and ribavirin for 48 weeks.
  • Patients in the 24 week arms will discontinue treatment at week 24 if they achieved a rapid virological response (RVR), defined as undetectable level of HCV RNA at week 4 ("RVR-guided"). Patients that do not achieve an RVR will continue on the standard of care until week 48.

    According to the current study design, patients will be enrolled as two cohorts, with randomization of the second larger cohort being initiated based on 12 week safety data of the first cohort.

    During 2009, we expect to provide updates on the progress of the trial.

    About R7128

    R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. R7128 has shown in vitro activity against all of the most common HCV genotypes (1, 2, 3 and 4).

    In a 4-week Phase 1 combination study that was conducted in 81 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated significant short-term antiviral activity with safety and tolerability comparable to placebo with SOC. Results from the 500mg, 1500mg and 1000mg dose cohorts (cohorts 1, 2 and 3) in 81 treatment-naive patients infected with HCV genotype 1 ind
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Pharmasset to Present at Two Upcoming Investor Conferences
    2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
    3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
    4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
    5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
    6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
    7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
    8. Pharmasset Joins Russell 3000 Index
    9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
    10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
    11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
    (Date:2/27/2015)... Feb. 27, 2015 Research and Markets ( ... Market Report of Trypsin" report to their offering. ... aims at providing comprehensive data on Trypsin globally and regionally ... North America , Latin America ... attention to Trypsin This report focuses on three ...
    (Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
    (Date:2/26/2015)... Feb. 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... denying motions for judgment notwithstanding the verdict, a new ...
    Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
    ... - Three private companies have formed a technology ... provide broadband wireless Internet ("Wi-Fi") access to residents, businesses ... Mayor Dave Cieslewicz. , ,The network will initially ... entire city. The initial downtown deployment is anticipated to ...
    ... Wis . -- A former paper converting plant in this ... Corp.'s push to become a major global player in ... group, produces various types of labels and thermal transfer ... challenges posed by the technology. The labels are intended to ...
    ... report suggests Wisconsin is slowly making progress when it comes ... as producing patents, investing in private research and development, and ... , ,There is no single reason, but a variety ... in a sea of global competition. , ,The report, ...
    Cached Biology Technology:New alliance to provide Wi-Fi network for City of Madison 2New alliance to provide Wi-Fi network for City of Madison 3New alliance to provide Wi-Fi network for City of Madison 4Wisconsin plant is part of NCR's global RFID initiative 2Wisconsin plant is part of NCR's global RFID initiative 3Wisconsin plant is part of NCR's global RFID initiative 4Heres why Wisconsins tech economy indicators are up 2Heres why Wisconsins tech economy indicators are up 3
    (Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
    (Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
    (Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
    Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
    ... in their response to sleep deprivation, but the biological ... Researchers have now found that a genetic difference in ... sensitive to the effects of sleep deprivation. The findings, ... the University of Surrey's Sleep Research Center, appear online ...
    ... upon a massive database established with funds from the ... of the National Institutes of Health (NIH), scientists have ... influenza A virus epitopes--the critical sites on the virus ... reported by researchers at the La Jolla Institute for ...
    ... first draft of the horse genome sequence has been ... use by biomedical and veterinary researchers around the globe, ... today. , The $15 million effort to sequence the ... of the horse (Equus caballus) was funded by the ...
    Cached Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2New details on how the immune system recognizes influenza 2New details on how the immune system recognizes influenza 3New details on how the immune system recognizes influenza 4Horse genome assembled 2Horse genome assembled 3
    FRACTALKINE [Human] (Recombinant)...
    ... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
    Argon Calibration Source...
    SHEEP ANTI ESCHERICHIA COLI...
    Biology Products: